Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…Abstract Number: 2765 • 2016 ACR/ARHP Annual Meeting
Practicing What We Preach? Do Psoriatic Arthritis Patients Treated at an Academic Medical Center Meet Caspar Criteria?
Background/Purpose: Psoriatic arthritis (PsA) is an autoimmune musculoskeletal disease with protean manifestations, and therefore can be difficult to diagnose. Although no diagnostic criteria are available, the…Abstract Number: 1293 • 2016 ACR/ARHP Annual Meeting
Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis
Background/Purpose: Between 8-39% of patients with cutaneous psoriasis may develop psoriatic arthritis (PsA). Subclinical inflammatory joint disease in patients with psoriasis is common. i,ii This study…Abstract Number: 2769 • 2016 ACR/ARHP Annual Meeting
Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?
Background/Purpose: “Composite psoriatic disease activity index (CPDAI)” includes 5 domains: peripheral joints, skin, enthesitis, dactylitis, and spinal manifestations in psoriatic arthritis (PsA) which is a…Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting
Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Background/Purpose: Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…Abstract Number: 3185 • 2016 ACR/ARHP Annual Meeting
Sensitivity Analysis for the Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Background/Purpose: Smoking is a strong risk factor for psoriasis and psoriatic arthritis, but several studies have found that smoking is inversely associated with the risk…Abstract Number: 1685 • 2016 ACR/ARHP Annual Meeting
Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe characteristics & potential risk factors(including treatment exposure) for all-cause mortality & malignancies (excluding NMSC) in psoriasis (PsO) patients (pts) with psoriatic arthritis…Abstract Number: 1686 • 2016 ACR/ARHP Annual Meeting
Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. In a phase 3 study, IXE was superior to placebo (PBO) in achieving…Abstract Number: 1708 • 2016 ACR/ARHP Annual Meeting
Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis
Background/Purpose: Psoriasis (PsO) is a chronic immune-mediated skin condition affecting ~3% of adults worldwide. Up to a third of PsO patients go on to…Abstract Number: 1716 • 2015 ACR/ARHP Annual Meeting
Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients with Plaque Psoriasis without Confirmed Psoriatic Arthritis: A US Analysis
Background/Purpose: Due to the high prevalence of PsA among patients with PsO,1 rheumatologists and dermatologists should recognize early signs and symptoms of joint involvement among…Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…Abstract Number: 2519 • 2015 ACR/ARHP Annual Meeting
Pregnancy in Psoriatic Arthritis: A Case Series
Background/Purpose: It is recognised that active disease in women with inflammatory arthritis is associated with adverse pregnancy outcomes. Most studies however, have focussed upon patients…
ACR Meeting Abstracts